← Back to Search

Inhaled Anesthetic

Volatile Anesthetics for COVID-19 (SAVE-ICU Trial)

Phase 3
Recruiting
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Receiving IV sedation by infusion or bolus for ≤72 hours to facilitate mechanical ventilation
≥ 18 years of age
Must not have
Severe brain injury that is likely to lead to sustained very low conscious levels or vegetative state
Suspect or evidence of high intracranial pressure
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Summary

This trial is testing whether using gases to keep patients sedated while on a breathing machine is more effective than using drugs.

Who is the study for?
Adults over 18, on mechanical ventilation for severe lung failure possibly due to COVID-19, and expected to need it for at least another day. They should have been sedated via IV for no more than 72 hours and not allergic to the trial drugs. Excluded are those with high brain pressure, severe brain injury, certain lung or neuromuscular conditions, contraindications to specific sedatives, pregnant women or patients unlikely to survive a day.
What is being tested?
The study compares inhaled anesthetics Sevoflurane and Isoflurane as alternatives for IV sedation in ICU patients with respiratory failure. It aims to see if these gases can improve survival rates, reduce time on ventilators and in hospitals by reducing lung inflammation and improving oxygen levels.
What are the potential side effects?
Potential side effects of Sevoflurane and Isoflurane may include dizziness, coughing, nausea or vomiting after waking up from sedation. Rarely they might cause confusion or agitation upon waking.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am on IV sedation for less than 72 hours to help with mechanical breathing.
Select...
I am 18 years old or older.
Select...
I am on strong pain medication through an IV to help with sedation or agitation while on a ventilator.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a severe brain injury likely to cause prolonged unconsciousness.
Select...
I might have high pressure inside my skull.
Select...
I am not allergic to the ingredients in the study drugs or to sevoflurane/isoflurane.
Select...
I have had surgery to remove one lung or use only one lung for breathing.
Select...
My breathing capacity is too low for certain inhaled treatments.
Select...
I have a severe muscle disorder like ALS or Guillain-Barre Syndrome that required ICU care and a breathing machine.
Select...
I cannot take certain sedatives due to severe reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Hospital Mortality
ICU-Free Days
Participant Quality of Life at 3 and 12 months after discharge
+1 more
Secondary study objectives
Adjunctive ARDS therapies
Delirium and Coma Free Days
Disability
+2 more

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Inhaled - volatile anestheticExperimental Treatment2 Interventions
The ICU patient will be randomized to either Isoflurane or Sevoflurane, whichever is available at the hospital. Dosage will be modified as per health care team guidance for the best treatment of the participant.
Group II: Non-randomizedActive Control1 Intervention
In this arm, ICU patients who cannot be randomized will receive inhaled or IV sedation as per available in their unit. This is done to try to obtain the maximum amount of information available from the patients present to our ICUs.
Group III: Standard CareActive Control1 Intervention
The ICU patient will be randomized to standard of care, which is any IV sedation supplied by the hospital. Dosage will be modified as per health care team guidance for the best treatment of the participant.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sevoflurane
FDA approved

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor
671 Previous Clinical Trials
1,563,877 Total Patients Enrolled

Media Library

Isoflurane Inhalant Product (Inhaled Anesthetic) Clinical Trial Eligibility Overview. Trial Name: NCT04415060 — Phase 3
Hypoxemic Respiratory Failure Research Study Groups: Non-randomized, Inhaled - volatile anesthetic, Standard Care
Hypoxemic Respiratory Failure Clinical Trial 2023: Isoflurane Inhalant Product Highlights & Side Effects. Trial Name: NCT04415060 — Phase 3
Isoflurane Inhalant Product (Inhaled Anesthetic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04415060 — Phase 3
~144 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top